NCT07329673 An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
| NCT ID | NCT07329673 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qbtech AB |
| Condition | Bi-Polar Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-01-01 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
Eligibility Criteria
Inclusion Criteria: * Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile; * Aged \> 6 years and \< 60 years old; * Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment; * Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures; * Have adequate sensory and physical ability to complete QbMobile; * Possess or have access to an iPhone model that supports QbMobile. Exclusion Criteria: * Intellectual disability designated by IQ\<70; * Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder; * Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation); * Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc); * Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain); * Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance; * Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07329673 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 60 Years, studying Bi-Polar Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07329673 currently recruiting?
Yes, NCT07329673 is actively recruiting participants. Contact the research team at robert.nolen@qbtech.com for enrollment information.
Where is the NCT07329673 trial being conducted?
This trial is being conducted at Miami, United States.
Who is sponsoring the NCT07329673 clinical trial?
NCT07329673 is sponsored by Qbtech AB. The trial plans to enroll 300 participants.